Trials / Withdrawn
WithdrawnNCT05693090
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Phase 1 Study of Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Kura Oncology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b) study. The purpose of this study is to measure safety, tolerability, and preliminary efficacy with the combination of tipifarnib with osimertinib in patients with advanced/metastatic EGFR-mutated non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tipifarnib | Oral administration |
| DRUG | Osimertinib | Oral administration |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2027-07-27
- Completion
- 2027-07-27
- First posted
- 2023-01-20
- Last updated
- 2023-03-06
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05693090. Inclusion in this directory is not an endorsement.